Warry E E, Willcox J L, Suter S E
Department of Clinical Sciences, College of Veterinary Medicine, North Carolina State University, Raleigh, NC.
J Vet Intern Med. 2014 Mar-Apr;28(2):529-37. doi: 10.1111/jvim.12302. Epub 2014 Jan 27.
Peripheral blood hematopoietic cell transplantation (PBHCT) is a feasible treatment option for dogs with B-cell lymphoma.
To examine apheresis and PBHCT outcomes in dogs diagnosed with T-cell lymphoma (TCL).
Fifteen client-owned dogs diagnosed with high-grade TCL.
After high-dose cyclophosphamide and rhG-colony-stimulating (rhG-CSF) factor treatment, peripheral blood mononuclear cells were collected using cell separators. The harvested cells then were infused after varying doses of total body irradiation (TBI). Postirradiation adverse effects were managed symptomatically and dogs were discharged upon evidence of hematopoietic engraftment.
More than 2 × 10(6) CD34+ cells/kg were harvested from 15/15 dogs. Thirteen of 15 (87%) dogs engrafted appropriately, whereas 2 (13%) of the dogs died in the hospital. One dog developed cutaneous B-cell lymphoma 120 days post-PBHCT. The median disease-free interval and overall survival (OS) of the 13 dogs transplanted in first remission from the time of PBHCT were 184 and 240 days, respectively. Stage and substage of disease at diagnosis had no effect on OS. Two of 13 (15%) dogs were alive 741 and 772 days post-PBHCT.
PBHCT may be considered as a treatment option for dogs with TCL.
外周血造血细胞移植（PBHCT）是B细胞淋巴瘤犬的一种可行治疗选择。
研究诊断为T细胞淋巴瘤（TCL）的犬的单采和PBHCT结果。
15只客户拥有的诊断为高级别TCL的犬。
在给予高剂量环磷酰胺和重组人粒细胞集落刺激因子（rhG-CSF）治疗后，使用细胞分离器采集外周血单个核细胞。然后在给予不同剂量的全身照射（TBI）后输注采集的细胞。对照射后的不良反应进行对症处理，当有造血植入证据时犬出院。
15只犬中有15只采集到超过2×10⁶个CD34⁺细胞/kg。15只犬中有13只（87%）成功植入，而2只（13%）犬在医院死亡。1只犬在PBHCT后120天发生皮肤B细胞淋巴瘤。13只在首次缓解期接受移植的犬从PBHCT时起的无病生存期和总生存期（OS）中位数分别为184天和240天。诊断时疾病的分期和亚分期对OS无影响。13只犬中有2只（15%）在PBHCT后741天和772天仍存活。
PBHCT可被视为TCL犬的一种治疗选择。
